Brett Hanscom

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 30 papers. Top paper: “Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women”.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

New England Journal of Medicine(2021)10.1056/nejmoa2101016

N/A

8.3DataRank · unranked

869 citations

Deborah Donnell, Meredith E. Clement, Brett Hanscom, Leslie Cottle, Lara E. Coelho +60 more

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

The Lancet(2022)10.1016/s0140-6736(22)00538-4

N/A

7.4DataRank · unranked

552 citations

James P. Hughes, Peter Bock, Samuel Gurrion Ouma, Portia Hunidzarira, Dishiki Kalonji +95 more

Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00261-8

N/A

2.0DataRank · unranked

68 citations

Brett Hanscom, Meredith E. Clement, Trần Việt Hà, Esper G. Kallás, Manya Magnus +25 more

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00140-6

N/A

1.1DataRank · unranked

33 citations

Sharon Mannheimer, Carmen A. Paez, Chenchen Yu, Theresa Gamble, Deborah Theodore +22 more

Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00200-x

N/A

0.580DataRank · unranked

14 citations

Brett Hanscom, Zhe Wang, Steven A. Safren, Christina Psaros, Deborah Donnell +61 more

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00053-23

N/A

0.510DataRank · unranked

29 citations

Jessica M. Fogel, Zhe Wang, Estelle Piwowar‐Manning, Ryan Kofron, Amber Moser +24 more

Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study)

Trials(2024)10.1186/s13063-023-07899-5

N/A

0.485DataRank · unranked

13 citations

Steven Shoptaw, Brett Hanscom, Laramie R. Smith, P. Andrew, Irene Kuo +12 more

Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084

Journal of the International AIDS Society(2025)10.1002/jia2.26401

N/A

0.442DataRank · unranked

18 citations

Brett Hanscom, Xu Guo, Clemensia Nkabiito, Patricia Mandima, Patricia Ntege Nahirya +17 more

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

The Lancet HIV(2024)10.1016/s2352-3018(24)00247-9

N/A

0.381DataRank · unranked

11 citations

Christopher B. Hurt, Kathryn E. Stephenson, Yunda Huang, Carmen A. Paez, Chenchen Yu +95 more

Causes and risk factors of death among people who inject drugs in Indonesia, Ukraine and Vietnam: findings from HPTN 074 randomized trial

BMC Infectious Diseases(2023)10.1186/s12879-023-08201-3

N/A

0.241DataRank · unranked

4 citations

Xu Guo, Trần Việt Hà, Zubairi Djoerban, Oleksandr Zeziulin, Vivian F. Go +11 more

Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.00994-24

N/A

0.165DataRank · unranked

2 citations

Kelong Han, Brett Hanscom, Xu Guo, Estelle Piwowar-Manning, Craig W. Hendrix +14 more

Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

UNC Libraries(2025)10.17615/8yt1-yt24

N/A

0.104DataRank · unranked

1 citations

Beatriz Grinsztejn, Omar Sued, Adeola Adeyeye, Estelle Piwowar‐Manning, Meredith E. Clement +26 more

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084

UNC Libraries(2023)10.17615/g6q4-an45

N/A

0DataRank · unranked

0 citations

Peter L. Anderson, Carrie Mathew, J.F. Rooney, L.R. Bushman, Juliet Mpendo +28 more

HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084

AIDS Research and Human Retroviruses(2024)10.1089/aid.2024.0049

N/A

0DataRank · unranked

5 citations

Deborah Persaud, Estelle Piwowar‐Manning, Paul Richardson, Joseph Szewczyk, Mark A. Marzinke +19 more

Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083

The Journal of Infectious Diseases(2025)10.1093/infdis/jiaf561

N/A

0DataRank · unranked

2 citations

Mark A. Marzinke, Xinnong Li, Deborah Donnell, Robert R. Bies, Craig W. Hendrix +16 more

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women

UNC Libraries(2025)10.17615/8kk4-f682

N/A

0DataRank · unranked

0 citations

Jared M. Baeten, Deborah Donnell, Glenda Gray, Linda‐Gail Bekker, Srilatha Edupuganti +9 more

Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

UNC Libraries(2025)10.17615/9zee-gb05

N/A

0DataRank · unranked

0 citations

Beatriz Grinsztejn, Mark A. Marzinke, Brett Hanscom, Alex R. Rinehart, Susan H. Eshleman +26 more

Examining stigma, social support, and gender differences in unsuppressed HIV viral load among participants in HPTN 065

Journal of Behavioral Medicine(2020)10.1007/s10865-020-00186-7

N/A

0DataRank · unranked

34 citations

Theresa Gamble, Wafaa El‐Sadr, Brett Hanscom, Elizabeth E. Tolley, Allysha C. Maragh‐Bass

Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084

Journal of the International AIDS Society(2025)10.1002/jia2.70056

N/A

0DataRank · unranked

0 citations

Brett Hanscom, Daniel Haines, Kimberly K. Scarsi, Yaw Agyei, Estelle Piwowar‐Manning +17 more

Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

The Journal of Infectious Diseases(2021)10.1093/infdis/jiab152

N/A

0DataRank · unranked

132 citations

Beatriz Grinsztejn, Jessica M. Fogel, Estelle Piwowar‐Manning, Maoji Li, Lei Weng +25 more

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084

The Journal of Infectious Diseases(2021)10.1093/infdis/jiab576

N/A

0DataRank · unranked

69 citations

Jessica M. Fogel, Estelle Piwowar‐Manning, Gordon Chau, Vanessa Cummings, Yaw Agyei +28 more

Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial

The Lancet HIV(2021)10.1016/s2352-3018(21)00153-3

N/A

0DataRank · unranked

5 citations

Deborah Donnell, Brett Hanscom, Marybeth McCauley, Beatriz Grinsztejn, Raphael J. Landovitz +1 more

HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac415

N/A

0DataRank · unranked

36 citations

Jessica M. Fogel, Elias K. Halvas, Estelle Piwowar‐Manning, Mark A. Marzinke, Ryan Kofron +25 more

Multiple Infection and Human Immunodeficiency Virus Superinfection Among Persons who Inject Drugs in Indonesia and Ukraine

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac441

N/A

0DataRank · unranked

3 citations

Wendy Grant‐McAuley, M. Kate Grabowski, Yinfeng Zhang, Paul Richardson, Estelle Piwowar‐Manning +13 more

Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083

The Lancet Regional Health - Americas(2023)10.1016/j.lana.2022.100416

N/A

0DataRank · unranked

21 citations

Marie‐Claude Boily, Brett Hanscom, Mia Moore, Jeffery Todd, Gabriela Paz‐Bailey +7 more

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women

Journal of the International AIDS Society(2023)10.1002/jia2.26118

N/A

0DataRank · unranked

11 citations

Fei Gao, James P. Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen +9 more

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

UNC Libraries(2023)10.17615/9m9q-rf23

N/A

0DataRank · unranked

0 citations

Bekezela Siziba, Dishiki Kalonji, M.C. Hosseinipour, S. Delany-Moretlwe, C.W. Hendrix +35 more

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

UNC Libraries(2023)10.17615/tc7d-x473

N/A

0DataRank · unranked

0 citations

R. Kofron, Kenneth H. Mayer, M. McCauley, Lei Weng, L.R. Bushman +24 more

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

UNC Libraries(2023)10.17615/2a0s-sa46

N/A

0DataRank · unranked

0 citations

B. Grinsztejn, Patrick Gonzales, S. Chariyalertsak, Nirupama Sista, Peter K Anderson +61 more

Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

UNC Libraries(2023)10.17615/rd9m-xs21

N/A

0DataRank · unranked

0 citations

Peter K Anderson, A. Rinehart, Lara E. Coelho, R.J. Landovitz, R. Kofron +25 more